BACKGROUND: Lower levels of quality asthma care among racially diverse populations might be due to inaccurate disease status assessments. The Asthma Control and Communication Instrument (ACCI) is a new tool that captures patient report of disease status during routine care. OBJECTIVE: We sought to test the ACCI's psychometric properties in a racially diverse population. METHODS: We performed a cross-sectional study. Subjects were recruited from specialist and generalist urban outpatient clinics. The ACCI and measures of asthma control, quality of life, lung function, and specialist rating of asthma status were collected. Four ACCI domains were separately validated: Acute Care, Bother, Control, and Direction. Principal component analysis, internal consistency, concurrent, discriminative, known-groups validity, and accuracy were evaluated. RESULTS: Two hundred seventy asthmatic patients (77% female subjects, 55% black) participated. ACCI Control domain internal consistency was 0.80. ACCI Bother, Control, and Direction domains showed strong concurrent validity with asthma control and quality-of-life measures (all P < .001). ACCI Acute Care and Direction domains showed strong concurrent validity with individual validation items (all P < .001). The ACCI Control domain discriminated clinically important levels of disease status measured by asthma control, quality of life (both P < .001), and percent predicted peak expiratory flow rate (P = .005) and was associated with specialist rating of disease status (P < .001), confirming known-groups validity. The accuracy of the ACCI Control domain in classifying patients with uncontrolled asthma was very good (area under the curve, 0.851; 95% CI, 0.742-0.95870). Results were similar for both black and white subjects. CONCLUSION: The ACCI is a promising clinical tool that measures asthma disease status during routine health care and is valid for use in both black and white populations.
BACKGROUND: Lower levels of quality asthma care among racially diverse populations might be due to inaccurate disease status assessments. The Asthma Control and Communication Instrument (ACCI) is a new tool that captures patient report of disease status during routine care. OBJECTIVE: We sought to test the ACCI's psychometric properties in a racially diverse population. METHODS: We performed a cross-sectional study. Subjects were recruited from specialist and generalist urban outpatient clinics. The ACCI and measures of asthma control, quality of life, lung function, and specialist rating of asthma status were collected. Four ACCI domains were separately validated: Acute Care, Bother, Control, and Direction. Principal component analysis, internal consistency, concurrent, discriminative, known-groups validity, and accuracy were evaluated. RESULTS: Two hundred seventy asthmatic patients (77% female subjects, 55% black) participated. ACCI Control domain internal consistency was 0.80. ACCI Bother, Control, and Direction domains showed strong concurrent validity with asthma control and quality-of-life measures (all P < .001). ACCI Acute Care and Direction domains showed strong concurrent validity with individual validation items (all P < .001). The ACCI Control domain discriminated clinically important levels of disease status measured by asthma control, quality of life (both P < .001), and percent predicted peak expiratory flow rate (P = .005) and was associated with specialist rating of disease status (P < .001), confirming known-groups validity. The accuracy of the ACCI Control domain in classifying patients with uncontrolled asthma was very good (area under the curve, 0.851; 95% CI, 0.742-0.95870). Results were similar for both black and white subjects. CONCLUSION: The ACCI is a promising clinical tool that measures asthma disease status during routine health care and is valid for use in both black and white populations.
Authors: William M Vollmer; Leona E Markson; Elizabeth O'Connor; E Ann Frazier; Marc Berger; A Sonia Buist Journal: Am J Respir Crit Care Med Date: 2002-01-15 Impact factor: 21.405
Authors: Anne L Fuhlbrigge; Robert J Adams; Theresa W Guilbert; Evie Grant; Paula Lozano; Susan L Janson; Fernando Martinez; Kevin B Weiss; Scott T Weiss Journal: Am J Respir Crit Care Med Date: 2002-10-15 Impact factor: 21.405
Authors: Robert A Nathan; Christine A Sorkness; Mark Kosinski; Michael Schatz; James T Li; Philip Marcus; John J Murray; Trudy B Pendergraft Journal: J Allergy Clin Immunol Date: 2004-01 Impact factor: 10.793
Authors: Gregory B Diette; Cecilia M Patino; Barry Merriman; Laura Paulin; Kristin Riekert; Sande Okelo; Kathy Thompson; Jerry A Krishnan; Ruth Quartey; Deanna Perez-Williams; Cynthia Rand Journal: Arch Intern Med Date: 2007-07-09
Authors: Sande O Okelo; Michelle N Eakin; Cecilia M Patino; Alvin P Teodoro; Andrew L Bilderback; Darcy A Thompson; Antonio Loiaza-Martinez; Cynthia S Rand; Shannon Thyne; Gregory B Diette; Kristin A Riekert Journal: J Allergy Clin Immunol Date: 2013-02-21 Impact factor: 10.793
Authors: Michelle M Cloutier; Michael Schatz; Mario Castro; Noreen Clark; H William Kelly; Rita Mangione-Smith; James Sheller; Christine Sorkness; Stuart Stoloff; Peter Gergen Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: Sande O Okelo; Michelle N Eakin; Kristin A Riekert; Alvin P Teodoro; Andrew L Bilderback; Darcy A Thompson; Antonio Loiaza-Martinez; Cynthia S Rand; Shannon Thyne; Gregory B Diette; Cecilia M Patino Journal: J Allergy Clin Immunol Pract Date: 2014-01-17
Authors: Kathleen F Harrington; Bin Zhang; Teresa Magruder; William C Bailey; Lynn B Gerald Journal: Pediatr Allergy Immunol Pulmonol Date: 2015-03-01 Impact factor: 1.349
Authors: Z Li; W L Leite; L A Thompson; H E Gross; E A Shenkman; B B Reeve; D A DeWalt; I-C Huang Journal: Clin Exp Allergy Date: 2016-10-21 Impact factor: 5.018
Authors: Pranav K Gandhi; Carolyn E Schwartz; Bryce B Reeve; Darren A DeWalt; Heather E Gross; I-Chan Huang Journal: Qual Life Res Date: 2016-04-09 Impact factor: 4.147